Doxycycline hyclate controlled-release - CollaGenex Pharmaceuticals

Drug Profile

Doxycycline hyclate controlled-release - CollaGenex Pharmaceuticals

Alternative Names: Controlled-release doxycycline hyclate; Doxycycline hyclate sustained release - CollaGenex/Shire; Periostat II; Periostat MR; Periostat SR; Sustained-release doxycycline hyclate - CollaGenex

Latest Information Update: 04 Feb 2008

Price : $50

At a glance

  • Originator CollaGenex Pharmaceuticals
  • Developer Supernus Pharmaceuticals
  • Class Antibacterials; Collagenases; Skin disorder therapies; Tetracyclines
  • Mechanism of Action Collagenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Periodontal disorders

Most Recent Events

  • 23 Nov 2004 CollaGenex has completed enrolment in a phase III trial for adult periodontitis in the US and UK
  • 05 Apr 2004 Phase-III clinical trials in Periodontal disorders in USA (PO)
  • 05 Apr 2004 Phase-III clinical trials in Periodontal disorders in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top